Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRHI Magnesita Regulatory News (RHIM)

Share Price Information for RHI Magnesita (RHIM)

Share Price is delayed by 15 minutes
Get Live Data
2,750.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 35.00 (1.296%)
Market Cap: £1.30b
RHIM Live PriceLast checked at - London Stock Exchange

Intraday RHI Magnesita Share Chart

Transaction in Own Shares

16 Dec 2020 07:00

RNS Number : 7752I
RHI Magnesita N.V.
16 December 2020
 

RHI Magnesita N.V.

 

("RHI Magnesita" the "Company" or the "Group")

 

Share buyback programme of up to €50 million

 

Further to its third quarter trading statement, on 22 October 2020 (the "Q3 Update"), RHI Magnesita confirms that the trading trends outlined then have continued, further strengthening the Group's confidence in its outlook. The Group continues to see gradual improvement in demand in its end markets and its order book and remains on track to deliver FY 2020 adjusted EBITA1 in line with current market expectations2. The Group has demand visibility extending into the beginning of 2021 across its order book, including now for the Industrial Projects business. 

 

RHI Magnesita's balance sheet remains strong, with liquidity of €1.2 billion and significant EBITDA covenant headroom. Due to this strong financial position, the Company's capital allocation strategy has been to prioritise investment to improve its competitive position and shareholder returns, which has included the reinstatement of the 2020 interim dividend. Given the continued resilient trading and cash generation of the Group, the Board is today taking further steps to enhance shareholder returns, through a share buyback programme of up to €50 million. On completion of this programme, the Board will review the merits of further share purchases.

 

The Board is confident that both the interim dividend which will be paid on 21 December 2020, and this share buyback, will have a limited impact on Group leverage. Furthermore, it will not compromise the Group's ability to execute its internal investment plans or its flexibility to pursue value enhancing acquisition opportunities which meet its investment criteria.

 

Details of the buyback programme

 

RHI Magnesita has, today, entered into a non-discretionary arrangement with Barclays Bank Ireland PLC ("Barclays") to purchase its ordinary shares, represented by depositary interests ("Shares"), on behalf of the Company (the "Arrangement").

 

The Arrangement allows Barclays to purchase up to 4,947,770 Shares of one euro nominal value each, during the programme, up to the value of €50 million in aggregate (the "Programme").

 

The Programme will commence on 16 December 2020 and end no later than 16 December 2021. These Share purchases under the Programme will be made on the Company's behalf and independently of, and uninfluenced by, the Company. The purpose of the share buyback is to reduce the Company's share capital in order to return value to our shareholders. The Company intends to hold the purchased shares in treasury. The Company may elect to suspend the Programme and subsequently restart it, provided that when electing to suspend or restart the Programme, the Company is not in a closed period and is not in possession of inside information in relation to its securities.

 

Any purchases of Shares pursuant to the Arrangement will be subject to the terms of the Arrangement with Barclays and, in any case, will be effected in a manner consistent with the general authority vested in the Company to repurchase Shares (as granted by shareholders at the Company's most recent annual general meeting held on 18 June 2020), the EU Market Abuse Regulation (596/2014), and Chapter 12 of the Financial Conduct Authority's Listing Rules.

 

References in this announcement, at any time after the end of the transition period relating to the United Kingdom's withdrawal from the EU, shall, in relation to anything done or to be done under or subject to UK laws, be deemed to refer to the equivalent UK provision of retained EU law.

 

1. Adjusted EBITA excludes other income and expenses

 

2. Current market expectation based on Company compiled consensus as at 22 October 2020 of 248 million

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (596/2014/EU).

 

Further information

 

Investors

Annabel Hill, Interim Head of Investor Relations +44 7792 034254

annabel.hill@rhimagnesita.com

 

Media

Matt Denham, Teneo +44 7825 735596

 

About RHI Magnesita

 

RHI Magnesita is the leading global supplier of high-grade refractory products, systems and solutions which are critical for high-temperature processes exceeding 1,200°C in a wide range of industries, including steel, cement, non-ferrous metals and glass. With a vertically integrated value chain, from raw materials to refractory products and full performance-based solutions, RHI Magnesita serves customers around the world, with around 13,000 employees in 35 main production sites and more than 70 sales offices. RHI Magnesita intends to leverage its leadership in terms of revenue, scale, product portfolio and diversified geographic presence to target strategically those countries and regions benefitting from more dynamic economic growth prospects.

 

Its shares have a premium listing on the London Stock Exchange (symbol: RHIM) and are a constituent of the FTSE 250 index, with a secondary listing on the Vienna Stock Exchange (Wiener Börse). For more information please visit: www.rhimagnesita.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFFDESIESSESE
Date   Source Headline
1st Jun 20268:49 amRNSTotal Voting Rights
13th May 20264:07 pmRNSResult of AGM
1st May 20268:57 amRNSTotal Voting Rights
29th Apr 20267:00 amRNSQ1 Trading Update
1st Apr 20269:11 amRNSTotal Voting Rights
26th Mar 20262:54 pmRNSNotice of AGM
10th Mar 202611:18 amRNSDirector/PDMR Shareholding
2nd Mar 20267:55 amRNSAnnual Financial Report
2nd Mar 20267:49 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNS2025 Full Year Results
13th Feb 20268:56 amRNSNotice of Results
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
10th Dec 20259:10 amRNSDirectorate change
10th Nov 20257:00 amRNSTrading Update
7th Nov 202511:48 amRNSDirectorate change
3rd Nov 202511:54 amRNSDirectorate change
1st Oct 20257:00 amRNSTotal Voting Rights
1st Aug 20257:00 amRNSTotal Voting Rights
30th Jul 20257:00 amRNS2025 Half Year Results
16th Jul 20257:00 amRNSNotice of Results
30th Jun 20258:29 amRNSDirector Declaration
2nd Jun 20258:53 amRNSTotal Voting Rights
29th May 20259:26 amRNSDirector/PDMR Shareholding
23rd May 20258:12 amRNSDirector Declaration
7th May 20254:11 pmRNSResult of AGM
7th May 20257:00 amRNSQ1 2025 Trading Update
1st May 20259:07 amRNSTotal Voting Rights
7th Apr 20253:36 pmRNSDirector/PDMR Shareholding
3rd Apr 20254:17 pmRNSDirector/PDMR Shareholding
1st Apr 20254:49 pmRNSDirector/PDMR Shareholding
1st Apr 20259:13 amRNSTotal Voting Rights
28th Mar 20254:12 pmRNSDirector/PDMR Shareholding
27th Mar 20253:30 pmRNSNotice of AGM
27th Mar 20252:50 pmRNSDirectorate Change
24th Mar 202512:32 pmRNSNotice of AGM
7th Mar 202510:13 amRNS2025 Long Term Incentive Plan Awards
27th Feb 20257:00 amRNS2024 Full Year Results
17th Feb 20257:00 amRNSNotice of Results
3rd Feb 20259:11 amRNSTotal Voting Rights
28th Jan 20251:59 pmRNSCompletion of Resco transaction
2nd Jan 20257:00 amRNSTotal Voting Rights
28th Nov 202410:09 amRNSDirector/PDMR Shareholding
21st Nov 20249:03 amRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSQ3 2024 Trading Update
7th Oct 202410:10 amRNSDirector/PDMR Shareholding
1st Oct 20247:00 amRNSTotal Voting Rights
27th Sep 202411:15 amRNSExercise of LTIP options by PDMR
19th Aug 202410:31 amRNSDirector/PDMR Shareholding
12th Aug 20242:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.